Aegle Therapeutics Corp. Announces Groundbreaking Results in Phase 1/2a Clinical Trial with AGLE-102
Aegle Therapeutics Corp., a pioneering company in the development of novel extracellular vesicle (EV) therapies, has recently announced the promising 12-week data for the first patient enrolled in a Phase 1/2a clinical trial of AGLE-102™ for treating severe second-degree burns. This marks a significant milestone in the treatment of rare and severe dermatological conditions, including […]
Unlocking Burn Healing: Aegle’s Breakthrough Therapy
Aegle Therapeutics Corp., a clinical-stage biotechnology company, has announced the initiation of its Phase 1/2a clinical trial, marking the dosing of its first patient. The trial will focus on the administration of AGLE-102™, a novel therapy designed to treat severe second-degree burns. AGLE-102™ is an investigational product made up of native extracellular vesicles, which are […]